-
Gill Boswell posted an update 4 hours, 10 minutes ago
01), lived in rural areas (p<0.01), and lived in areas with many families living in poverty (p<0.01). In adjusted models, enrollees with an ED claim reported significantly worse access to care (β-4.83; 95%CI -9.29,-0.38; p=0.03).
The management of urgent care concerns for adults with hematologic malignancies remains an important clinical…[Read more]
-
Gill Boswell posted an update 1 day, 4 hours ago
The results provide a theoretical knowledge for the prevention of insulin resistance in T2D of pea-derived peptides and lay the foundation for the development of functional products and drugs in the future.While the traditional clinical trial design lays emphasis on testing the treatment effect between randomly assigned groups, it ignores the role…[Read more]
-
Gill Boswell posted an update 2 days, 4 hours ago
CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a valuable new treatment option for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. The aim of this review is to give an overview of the pivotal phase I/II trials, emerging real-world evidence and ongoing trials.
For decades, attempts at improvement of the…[Read more]
-
Gill Boswell posted an update 3 days ago
erebral blood flow responses to hypoxia and anaemia. The fail-safe model of carotid body glomus cell control of intracellular hydrogen ion concentration also yielded results similar in form to observations of carotid sinus nerve responses to hypoxia and hypercapnia. The ability of these simple models to simulate experimental observations…[Read more]
-